New Risk • Jun 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£26.4m market cap, or US$34.8m). New Risk • Feb 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£35.1m market cap, or US$47.9m). Reported Earnings • Jan 05
First half 2026 earnings released: EPS: UK£0 (vs UK£0 in 1H 2025) First half 2026 results: EPS: UK£0 (in line with 1H 2025). Revenue: UK£364.4k (down 54% from 1H 2025). Net loss: UK£310.2k (loss widened 95% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.3m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.2m). Reported Earnings • Nov 02
Full year 2025 earnings released: EPS: UK£0 (vs UK£0 in FY 2024) Full year 2025 results: EPS: UK£0 (in line with FY 2024). Revenue: UK£1.29m (up 61% from FY 2024). Net loss: UK£452.7k (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Board Change • Oct 30
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Anuncio • Oct 30
Provexis plc to Report Q2, 2026 Results on Oct 30, 2025 Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025 Anuncio • Sep 30
Provexis plc, Annual General Meeting, Nov 21, 2025 Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom New Risk • Jul 20
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£17.4m market cap, or US$23.3m). New Risk • May 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£13.4m market cap, or US$17.9m). Reported Earnings • Jan 03
First half 2025 earnings released: EPS: UK£0 (vs UK£0 in 1H 2024) First half 2025 results: EPS: UK£0 (in line with 1H 2024). Revenue: UK£785.3k (up 103% from 1H 2024). Net loss: UK£159.1k (loss narrowed 40% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. New Risk • Dec 31
New major risk - Revenue and earnings growth Earnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (UK£15.3m market cap, or US$19.1m). New Risk • Nov 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£191k free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£802k revenue, or US$1.0m). Market cap is less than US$100m (UK£15.9m market cap, or US$19.9m). Reported Earnings • Oct 01
Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023) Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Anuncio • Oct 01
Provexis plc, Annual General Meeting, Oct 25, 2024 Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom New Risk • Jul 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£13.6m market cap, or US$17.6m). New Risk • Mar 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£14.1m market cap, or US$17.8m). New Risk • Dec 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£521k free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (UK£390k revenue, or US$490k). Minor Risk Market cap is less than US$100m (UK£14.9m market cap, or US$18.7m). Reported Earnings • Oct 01
Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022) Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Anuncio • Sep 30
Provexis plc, Annual General Meeting, Oct 26, 2023 Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters. New Risk • Jul 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£12.8m market cap, or US$16.2m). Reported Earnings • Dec 31
First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022) First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Sep 30
Full year 2022 earnings released: EPS: UK£0 (vs UK£0 in FY 2021) Full year 2022 results: EPS: UK£0 (in line with FY 2021). Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 02
Full year earnings released - UK£0.0002 loss per share Over the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year. 